From: Prognostic models for breast cancer: a systematic review
Characteristics | Model development studies | Internal validation studies | External validation studies |
---|---|---|---|
Number of studies | 54 studies | 42 studies | 49 studies |
Number of models | 58 models | 42 models | 17 models |
Year of publication | 1982–2016 | 1982–2016 | 1987–2016 |
Study design | |||
 Prospective | 2 studies | 2 studies | 0 study |
 Retrospective | 32 studies | 23 studies | 30 studies |
 Unknown | 20 studies | 18 studies | 19 studies |
Source of data | |||
 Population-based | 14 studies | 11 studies | 12 studies |
 Hospital-based | 31 studies | 29 studies | 33 studies |
 RCT-based | 6 studies | 1 study | 4 studies |
 Unknown | 3 studies | 2 studies | 0 study |
Sample size | 75–433,272 | 30–433,272 | 48–387,262 |
Number of events | |||
 Deaths | 27–24,610 | 27–24,610 | 11–3902 |
 Recurrences | 5–1030 | 5–950 | 9–1188 |
Country of participants | |||
 Europe | 24 studies | 22 studies | 29 studies |
 North America | 13 studies | 8 studies | 7 studies |
 Asia | 11 studies | 10 studies | 11 studies |
 Others | 2 studies (Australia) | 0 study | 3 studies (1 Australia. 1 New Zealand, 1 Brazil) |
Strengths concluded by the authors of the selected studies | |||
 Adhere to good practice | 1 study | 1 study | 0 study |
 Large sample size | 2 studies | 2 studies | 4 studies |
 Patients diagnosed recently | 1 study | 1 study | 0 study |
 Homogeneous source of data | 2 studies | 2 studies | 1 study |
 Low proportion of missing data | 0 study | 0 study | 1 study |
Weaknesses concluded by the authors of the selected studies | |||
 Missing data | 11 studies | 11 studies | 8 studies |
 Small sample size | 3 studies | 3 studies | 9 studies |
 Patients treated with obsolete methods | 4 studies | 4 studies | 3 studies |
 Heterogeneous source of data | 3 studies | 3 studies | 0 study |
 Selection bias | 2 studies | 2 studies | 0 study |
 Short-time follow-up | 1 study | 1 study | 0 study |